Ivan Hyep is CFO at Bicara Therapeutics Inc. (BCAX). They have made 2 open-market trades across 1 company since 2025, most recently 2026-08-10.
CIK 0002034668
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| BCAX | 129,855 | $2.2M |
Shares reported on the most recent Form 4, priced at the 2026-08-12 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BCAX | SELL · 10b5-1 | 2026-08-10 | 2026-08-12 | $27.97 | $350K | -3.2% | -6.2% | — |
| BCAX | SELL · 10b5-1 | 2026-07-08 | 2026-07-10 | $28.85 | $808K | -0.2% | -1.3% | -38.6% |
| BCAX | SELL · 10b5-1 | 2026-05-21 | 2026-05-26 | $20.42 | $188K | -10.6% | +17.9% | +5.4% |
| BCAX | SELL · 10b5-1 | 2026-04-21 | 2026-04-22 | $23.00 | $212K | -3.7% | -7.9% | +19.4% |
| BCAX | SELL · 10b5-1 | 2026-03-23 | 2026-03-24 | $18.52 | $341K | +12.4% | +23.1% | +32.3% |
| BCAX | SELL | 2026-03-03 | 2026-03-05 | $18.22 | $301K | +5.9% | +14.2% | +9.5% |
| BCAX | SELL | 2026-01-22 | 2026-01-26 | $18.15 | $34K | -8.3% | +6.3% | +36.5% |
| BCAX | SELL · 10b5-1 | 2025-12-22 | 2025-12-23 | $18.31 | $168K | -7.5% | +0.5% | +5.0% |
| BCAX | SELL · 10b5-1 | 2025-11-21 | 2025-11-25 | $18.54 | $671K | +2.7% | -8.7% | -10.9% |
| BCAX | SELL · 10b5-1 | 2025-10-09 | 2025-10-10 | $18.23 | $234K | -11.3% | -24.9% | -10.7% |
| BCAX | SELL · 10b5-1 | 2025-10-06 | 2025-10-08 | $18.21 | $1.1M | -9.1% | -18.2% | -9.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.